کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3364748 1592139 2009 13 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups
چکیده انگلیسی

SummaryObjectiveTo measure the impact of invasive aspergillosis infection on US hospital costs and financial performance across different patient populations.MethodsHospital discharge data for patients with a primary or secondary diagnosis of aspergillosis were extracted from the 2003 Nationwide Inpatient Sample (NIS) and the fiscal year 2003 (FYO3) Medicare Provider Analysis and Review (MedPAR) file. The data on patient demographics, length of stay (LOS), hospital charges, estimated costs, and reimbursement levels were reported. After controlling for comorbidities, operative procedures, and diagnosis-related group (DRG) assignment, the clinical and economic outcomes were compared for patients with and without aspergillosis.ResultsThe NIS contains a total of over 38 million projected hospital discharges. From these, 10 400 aspergillosis cases were identified across 171 DRGs, resulting in a US incidence rate of 36 per million per year. The mean age of aspergillosis patients was 55.6 years, with 53.4% male and 67.9% Caucasian. The median (mean) LOS per aspergillosis patient was 10 (17.7) days, with a median (mean) total hospital charge (THC) of $44 845 ($96 731). Among the patient subgroups analyzed, the median (mean) THC per patient ranged from $47 252 ($82 946) for HIV to $413 200 ($442 233) for bone marrow transplant (BMT). When compared to the non-aspergillosis patient population, the data showed a significant increase in LOS, THC, and hospital costs. Furthermore, the higher hospital costs associated with aspergillosis patients were not matched by similar increases in reimbursements, resulting in a greater financial loss for hospitals. The mean reimbursement-to-cost ratio for aspergillosis cases across the DRGs analyzed was 0.80.ConclusionsAspergillosis affects a wide range of patient groups and has a negative economic impact across many DRGs. Improved prevention, diagnosis, and patient management strategies can help mitigate these effects on hospital financial performance.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Infectious Diseases - Volume 13, Issue 1, January 2009, Pages 24–36
نویسندگان
, , , , ,